Ridgetech, Inc.

About

Incorporated in 2025 with headquarters in Hangzhou, Ridgetech, Inc. is a rapidly growing, online and offline wholesale distributor of pharmaceutical and other healthcare products in China. Ridgetech actively trades on popular online distribution platforms nationwide and has its own online distribution platform. The Company believes that trading on these platforms offers greater opportunities to distribute pharmaceutical products nationwide. Ridgetech is a network technology company mainly engaged in B2B and new wholesale business of medicines, medical devices, health foods, cosmetics and daily necessities. The company has a professional sales team with service skills, and it has a well-established and high-quality sales network covering Zhejiang Province. Ridgetech’s business performance has been steadily improving year by year. As of December 2024, Ridgetech has more than 5000 varieties of products and proudly serves over 150,000 customers.

Verified company data

Shares outstanding

3,629,540

Leadership

Frank Ming Zhao (Chief Financial Officer, Served as CFO since August 2011, previously a senior manager at CFO Oncall, Inc. and a senior auditor at Sherb & Co., LLP. Licensed CPA with degrees in accounting from Central University of Finance and Economic and professional accounting from the University of Washington.), Genghua Gu (Independent Director, Retired physician and professor with extensive experience in stomatology and hospital management. Served as Vice President of Women’s Hospital of Zhejiang University and has held various governmental and educational roles.), Jiangliang He (Independent Director, Professional attorney and partner at Dentons China since 2008, with previous experience at Zhejiang Jiuyao law firm and as a law professor at Hangzhou School of Law. Holds a law degree from Beijing University.), Wu (Independent Director, Graduated from Jiangxi Medical College, worked as a physician for eight years, then spent 18 years at GlaxoSmithKline in various sales and strategy roles, currently COO at Cardinal Health China Pharmaceutical Co., Ltd.)

Verified data last updated: 2026-08-14

Recent filings

• Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 19342025-03-03 · rdgt_2025-03-03_14-41-03.pdf→
• Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 19342025-02-05 · rdgt_2025-02-05_08-00-00.pdf→
• Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 19342025-02-03 · rdgt_2025-02-03_13-30-06.pdf→
• Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 19342025-01-15 · rdgt_2025-01-15_14-00-34.pdf→
• [Amend] General statement of acquisition of beneficial ownership2024-11-14 · rdgt_2024-11-14_21-15-11.pdf→
• Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 19342024-11-12 · rdgt_2024-11-12_21-15-03.pdf→
• Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 19342024-10-21 · rdgt_2024-10-21_19-15-04.pdf→
• [Amend] General statement of acquisition of beneficial ownership2024-09-03 · rdgt_2024-09-03_11-50-20.pdf→